Janone inc. executes term sheet to acquire soin therapeutics llc

The acquisition of soin will provide janone with its second clinical stage product las vegas , sept. 16, 2022 /prnewswire/ -- janone inc. ("janone") (nasdaq: jan), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has executed a term sheet to acquire soin therapeutics llc and its product, a patent-pending, novel formulation of low dose naltrexone.
JAN Ratings Summary
JAN Quant Ranking